Articles
<![CDATA[Chronic limb ischemia manifestation in COVID-19 infection: awareness and treatment in primary care ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Siregar, Reynaldo Halomoan]]>;
<![CDATA[Kusharsamita, Hillary]]>
<![CDATA[ Universa Medicina Vol. 40 No. 2 (2021) ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Trisakti ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.18051/UnivMed.2021.v40.166-175
<![CDATA[Chronic limb ischemia (CLI) is a type of peripheral arterial disease (PAD) that is still underdiagnosed and undertreated despite the increasing incidence, thus becoming a global health burden. And CLI reflects the local manifestations of a lethal systemic disease — atherosclerosis. If left untreated, chronic limb ischemia can result in major limb loss. In this pandemic era, limb ischemia has become one of several clinical manifestations that occur in patients with COVID-19 infection. Systemic inflammation in COVID-19 infection, direct viral infection, hypercoagulable state, and hyperinflammatory response are responsible for damage to the arterial system, causing endothelial dysfunction. Diagnosing PAD has become a challenge especially in the early stage and in the asymptomatic phase. The untreated condition could lead to the development of CLI. The primary physicians in the primary health facilities hold an important role in the early diagnosis and management of patients with CLI symptoms or with risk factors of CLI, especially in patients who have experienced COVID-19 infection. Due to the limitation of diagnostic testing modalities at primary health facilities, the physician can assess the ankle-brachial index (ABI) to determine the presence of CLI. Management of the disease is different for every patient and is customized based on the other comorbidities. Risk factors should be controlled in order to achieve a better outcome. A good management strategy will improve the quality of life of the patient. This review will discuss the occurrence of CLI in COVID-19 infection.]]>
<![CDATA[PSORIASIS AND CARDIOVASCULAR DISEASE: IS IT CORRELATE? ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Candra, Wincent]]>
<![CDATA[ Syifa'Medika Vol 12, No 2 (2022): Syifa' MEDIKA: Jurnal Kedokteran dan Kesehatan ]]>
Publisher : <![CDATA[Faculty of Medicine ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.32502/sm.v12i2.3935
<![CDATA[Psoriasis is a common chronic inflammatory disease. This disease can cause a significant reduction in a person's quality of life. Systemic inflammation of psoriasis is thought to play a role in increasing the incidence of cardiovascular disease. Cardiovascular disease in psoriasis patients is a significant economic burden. Therefore, it is important for a doctor to understand and prevent the occurrence of cardiovascular disease in this population. This review aims to review the relationship between psoriasis and the incidence of cardiovascular disease, the underlying mechanisms, and the impact of the treatment of each disease on the other. There are overlapping risk factors for these two conditions. The underlying pathology of these two diseases is inflammation. The inflammation and treatment of one of these diseases might have an impact on the other. Psoriasis and cardiovascular disease are closely related to each other.]]>
<![CDATA[Case Reports of Left Atrial Myxoma in Elderly and Children ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Surya, Steven Philip]]>;
<![CDATA[Manuputty, Ferel]]>;
<![CDATA[Lasanudin, Hengkie Frankie]]>;
<![CDATA[Prawara, Ananta Siddhi]]>
<![CDATA[ Sains Medika: Jurnal Kedokteran dan Kesehatan Vol 12, No 1 (2021): June 2021 ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Islam Sultan Agung (UNISSULA), Indonesia ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (880.24 KB)
|
DOI: 10.30659/sainsmed.v12i1.11632
<![CDATA[Introduction: Cardiac myxoma is a rare heart disease. Cardiac myxoma can manifest in both intracardiac and extracardiac. This report describes the importance of a careful history taking, physical examination, echocardiography, and complete surgical resection for the management of atrial myxoma in two patients.Case Reports: We reported two cases: a 64 years old female and a 16 years old male with neurological deficit as the chief complaint. The two patients underwent brain imaging and echocardiography evaluation. Both were diagnosed with left atrial myxoma and brain infarction. Surgical resection of the left atrial myxoma was successfully done in both patients and afterward, both were being monitored in the outpatient clinic. During follow up, a gradual clinical improvement can be seen in the right extremities. Echocardiography examination was conducted at 1 month, 3 months, and 6 months follow-ups for both patients and no abnormalities were found. Discussion: Atrial myxomas are the most common primary cardiac tumors. Systemic embolization in atrial myxoma is uncommon manifest as neurological deficit with reported incidence around 20-35%. On the other hand, in stroke or transient ischemic attack patients, atrial myxoma were found in 1 out of 250 young adults and 1 out of 750 older patients. Transthoracic echocardiography (TTE) has up to 95% sensitivity on diagnosing atrial myxoma. The long-term prognosis of the patients when diagnosed and managed correctly is very good and surgery is curative with recurrence rate 1-3%. The patients in our case reports showed gradual clinical improvement with no sign of myxoma recurrence during follow up.Conclusion: Stroke is one of the extracardiac manifestations of atrial myxoma. Thus, it is crucial to evaluate the presence of atrial myxoma in stroke patients. The use of TTE is important in diagnosing atrial myxoma. Resection of atrial myxomas is curative with excellent long-term prognosis and low chance of recurrences.]]>
<![CDATA[Supraventricular Tachycardia Induced by Cisplatin in a Patient with Breast Cancer: A Case Report ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Kusharsamita, Hillary]]>
<![CDATA[ Indonesian Journal of Cancer Vol 18, No 2 (2024): June ]]>
Publisher : <![CDATA[http://dharmais.co.id/ ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.33371/ijoc.v18i2.1066
<![CDATA[Introduction: Cisplatin is one of the most extensively used chemotherapeutic agents for treating many malignancies. Cisplatin chemotherapy, on the other hand, is linked to cardiotoxicity, which may vary from silent arrhythmias to heart failure to sudden cardiac death. In this article, we describe a case of supraventricular tachycardia induced by cisplatin in a breast cancer patient. Case Presentation: Our patient had no history of heart disease and had SVT during cisplatin administration. This condition resolved when the infusion was stopped and amiodarone was administered intravenously. The electrolyte levels were within the usual range. No abnormalities were detected on her echocardiography imaging. Primary cardiotoxicity from cisplatin was subsequently determined to be this patient's root cause of SVT. The patient also had an excellent response to the subsequent cycles of treatment. Conclusions: It is important to note that cisplatin therapy is associated with cardiac toxicity. Arrhythmias such as SVT have been associated with chemotherapy drugs. Hence the ECG has to be closely monitored during cisplatin administration. In addition, An ECG and echocardiogram should be done regularly to rule out the possibility of a secondary form of chemotherapy-induced arrhythmia. ]]>
<![CDATA[Management of Heart Failure in the Hospital: A Clinical Approach ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Syukran]]>
<![CDATA[ Ahmad Dahlan Medical Journal Vol. 4 No. 2 (2023): November 2023 ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
<![CDATA[Despite tremendous breakthroughs in drug-based and device-based therapy, heart failure continues to be a serious and growing public health issue linked with substantial disability, frequent hospitalization, and large economic expenditures. Complex therapeutic options in a population with a high frequency of comorbidity and overall frailty hinder clinical care. In recent years, significant progress has been made in the care of heart failure (HF). In this study, the most recent available evidence, the indications provided by worldwide guidelines, and expert opinion on the optimal treatment for individuals with HF will be discussed. This review, according to the authors, bridges the gap between guidelines and clinical practice and presents recommendations to improve HF management.]]>
<![CDATA[Peri-Myocardial Infarction Pericarditis After Single Stent Early PCI on a STEMI Patient: A Rare Case of Outpatient in Urban Setting ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Jusuf, Axel]]>
<![CDATA[ Ahmad Dahlan Medical Journal Vol. 5 No. 1 (2024): May 2024 ]]>
Publisher : <![CDATA[Universitas Ahmad Dahlan ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
<![CDATA[Peri-Myocardial Infarction Pericarditis (PMIP), can occur a few days following a myocardial infarction (MI). PMIP frequently exhibits the auscultatory findings of a pericardial friction rub and pericardial effusion. On the other hand, relatively little is known about the management approach. This study aims to report a patient with PMIP following successful revascularization via Percutaneous Coronary Intervention (PCI) for a recent MI. A 50-year-old male was brought to our Outpatient Clinic with chest pain of two days onset. The patient experienced radiating chest pain, cold sweat, heartburn, and general fatigue. ECG shows extensive anterior ST-elevation myocardial infarction (STEMI), and Troponin T was elevated >2000 ng/L. The patient underwent PCI with single stent deployment. Three days later, the patient experienced dyspnea with Transthoracic Echocardiography (TTE) findings consistent with Early PMIP. The patient was discharged after completing full conservative therapy with good results. The clinical findings of PMIP alone may be subtle and go unnoticed. Clinicians should maintain a high level of suspicion in the era of revascularization and develop a strategic plan for timely diagnosis and management. While anti-inflammatory medical therapy is aimed at reducing inflammation and preventing recurrences and progression of the disease, further research is needed to establish prognostic significance and management strategy since clinically diagnosed PMIP has a benign and self-limiting nature.]]>
<![CDATA[Peran dari Biopsi Miokard: Review dari Sudut Pandang Kardiologis ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Nurusshofa, Zahra]]>;
<![CDATA[Hosea, Grace Trifena]]>
<![CDATA[ UMI Medical Journal Vol 9 No 1 (2024): UMI Medical Journal ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Muslim Indonesia ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.33096/umj.v9i1.258
<![CDATA[Latar Belakang: Endomyocardium biopsy (EMB) merupakan salah satu modalitas diagnosis invasif yang kontroversial dan sudah mulai berkurang karena teknologi pencitraan semakin berkembang dan bisa digunakan untuk mendiagnosis penyakit jantung lain tanpa melakukan prosedur invasif. Studi ini bertujuan untuk membahas perkembangan dan peran dari EMB sebagai modalitas diagnostik. Isi: EMB sering digunakan untuk menilai penolakan transplantasi jantung dan mendiagnosis penyakit kardiomiopati inflamatorik dan infiltratif. Akses melalui arteri radialis pada EMB ventrikel kiri berhubungan dengan komplikasi vaskular yang lebih rendah. Vena jugularis interna umum digunakan untuk EMB ventrikel kanan pada pasien transplantasi jantung, sedangkan vena femoralis kanan untuk pasien yang tidak menjalani transplantasi. Prosedur EMB memiliki komplikasi aritmia, abnormalitas konduksi, kerusakan katup, emboli, perforasi, dan kematian dan komplikasi tersebut sangat bergantung terhadap pengalaman operator. Kesimpulan: EMB sebagai alat diagnosis dapat digunakan terutama saat alat diagnosa lainnya tidak memadai untuk menegakkan diagnosa dan juga untuk memonitor reaksi penolakan transplantasi jantung. Untuk meminimalisir trauma dan meningkatkan akurasi, dikembangkan alat mikro biopsi yang sampai sejauh ini masih di uji coba kepada hewan.]]>
<![CDATA[TATALAKSANA PENYAKIT KATUP MITRAL: TINJAUAN SINGKAT ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Hosea, Grace Trifena]]>
<![CDATA[ Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan Vol 5 No 3 (2023): December ]]>
Publisher : <![CDATA[Fakultas Kedokteran Universitas Alkhairaat ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.31970/ma.v5i3.133
<![CDATA[Penyakit katup mitral merupakan salah satu penyakit katup jantung paling umum namun jarang dibahas. Salah satu penyebab tersering penyakit katup mitral adalah penyakit jantung rematik yang sering terjadi di negara berkembang. Diagnosis penyakit katup mitral bisa ditegakkan dengan transthoracic echocardiogram (TTE) dengan pencitraan 2 dimensi (2D) dan pemeriksaan doppler. Regurgitasi mitral merupakan penyakit katup jantung paling umum dan stenosis mitral paling sering disebabkan karena penyakit jantung rematik. Tatalaksana standar untuk penyakit katup mitral adalah operasi penggantian atau perbaikan katup, namun tidak semua pasien menjalani operasi dan mendapat tatalaksana yang tidak adekuat. Sedangkan tatalaksana farmakologis hanya untuk meringankan gejala dan disesuaikan dengan terapi farmakologi berbasis pedoman pada gagal jantung. Paduan tatalaksan untuk penyakit katup mitral masih belum jelas karena kurangnya penelitian dan publikasi, sehingga perlu dilakukan penelitian lebih lanjut.]]>
<![CDATA[Diagnosis dan Tatalaksana Miokarditis Pada Anak: Tinjauan Pustaka ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Afiyani, Nadia]]>
<![CDATA[ ANATOMICA MEDICAL JOURNAL | AMJ Vol 7, No 1 (2024) ]]>
Publisher : <![CDATA[Universitas Muhammadiyah Sumatera Utara ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.30596/amj.v7i1.15815
<![CDATA[Miokarditis merupakan peyakit inflamasi yang terjadi pada otot jantung yang mana memiliki tampilan klinis yang beragam sehingga seringkali sulit terdiagnosis terutama pada anak-anak. Meskipun begitu, miokarditis pada anak berpotensi menimbulkan manifestasi klinis yang berkepanjangan di masa depan. Hingga saat ini, masih dilakukan banyak penelitian mengenai cara mendiagnosis dan tatalaksana yang paling sesuai pada anak-anak dengan mempertimbangkan kemungkinan komplikasi seminimal mungkin. Penulisan tinjauan pustaka ini bertujuan untuk membahas mengenai diagnosis dan pengelolaan miokarditis pada anak-anak. Diagnosis menggunakan pencitraan resonansi magnetik jantung perlu mendapatkan perhatian khusus karena dapat memperlihatkan proses inflamasi akut pada otot jantung secara tidak invasif. Di sisi lain, masih banyak perdebatan mengenai tatalaksana terbaik bagi miokarditis pada anak-anak dan diperlukan penelitian lebih lanjut lagiKata Kunci : anak, diagnosis, miokarditis, tatalaksana]]>
<![CDATA[Patofisiologi dan Manajemen Defisiensi Zat Besi pada Gagal Jantung: Sebuah Tinjauan Literatur ]]>
<![CDATA[Laksono, Sidhi]]>;
<![CDATA[Hertanto, Yoseph Jeffry]]>
<![CDATA[ Journal of Islamic Medicine Vol 7, No 2 (2023): JOURNAL OF ISLAMIC MEDICINE EDISI SEPTEMBER 2023 ]]>
Publisher : <![CDATA[Faculty of Medicine and Health Science, Universitas Islam Negeri Maulana Malik Ibrahim ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.18860/jim.v7i2.21513
<![CDATA[The human body needs iron to function. Deficiency of iron causes inefficient use of oxygen and decreased oxygen availability. Iron deficiency is diagnosed when serum ferritin concentration is less than 100 ng/ml or concentration of ferritin is 100-299 ng/mL with transferrin saturation less than 20% in patients with heart failure. Several possible mechanisms are proposed as a cause for iron deficiency, such as; decreased food intake, increase hepcidin secretion that causes poor iron absorption, inflammation of reticuloendothelial system that causes iron leakage and loss of blood from gastrointestinal tract. Management of iron deficiency in heart failure is focused on iron supplementation, either orally or intravenously. Oral iron supplementation is generally considered less effective and may cause severe gastrointestinal side effects. Current guidelines also support use of IV therapy. Currently, several novel therapies in development focus on iron metabolism.]]>
